Photo of Karen Luong

Karen Luong

Subscribe to Karen Luong's Posts

Karen guides clients through high-stakes litigation, focusing on product liability and mass tort matters.

Manufacturers, construction companies, automotive manufacturers and retailers, insurers, contractors, suppliers and business owners are a few of the clients relying on Karen’s experience, counsel and defense. She is well versed in complex litigation involving toxic products, materials and chemicals. Karen regularly represents clients in state and federal court in matters of product liability, premises liability, personal injury and other complex allegations. She is known for her ability to defend client reputation along with the legal claims at hand.

Karen is the co-founder and co-lead of the firm’s Psychedelic and Emerging Therapies practice group. This groundbreaking group guides researchers, manufacturers, investors, clinicians and other participants around and through the myriad obstacles that result from the patchwork of state and federal laws regulating Schedule I controlled substances.

In addition to Karen’s focus on psychedelic law and complex products liability, she also has experience representing clients in general commercial litigation, business litigation and the cannabis industry.

Follow:Read more about Karen LuongKaren's Linkedin Profile

On December 12, 2023, the Multidisciplinary Association for Psychedelic Studies Public Benefit Corporation (“MAPS PBC”) announced it has submitted a new drug application (“NDA”) to the FDA for the use of 3,4-Methylenedioxymethamphetamine (“MDMA”) for the treatment of post-traumatic stress disorder (“PTSD”).

DEA waivers regarding the Ryan Haight Act could play a major role in telehealth’s future.

In the first decade of the 21st century, deaths attributable to overdoses of prescription drugs saw an alarming spike in volume, led higher by a tripling of deaths due to opioid use. Amid this surge, Congress enacted the Ryan Haight Online Pharmacy Consumer Protection Act in 2008 as part of an attempt to rein in the burgeoning online marketplace for prescription drugs—particularly those involving controlled substances—which had largely evaded prior enforcement actions.